Experts are excitedly focused on retatrutide, a novel medication developed by Eli Lilly, as a significant breakthrough in physique reduction . Unlike many existing approaches, retatrutide is a twin-action receptor targeting equally GLP-1 and GIP, chemicals that influence appetite and blood sugar